Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases

Annals of Surgical Oncology

Volumn 5, Issue 8, 1998, Pages 706-712

  Kokudo, Norihiro ^a   Seki, Makoto ^a   Ohta, Hirotoshi ^a   Azekura, Kaoru ^a   Ueno, Masashi ^a   Sato, Tadao ^a   Moroguchi, Akihito ^a   Matsubara, Toshiki ^a   Takahashi, Takashi ^a   Nakajima, Toshifusa ^a   Aiba, Keisuke ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal metastases; Hepatic resection

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; TEGAFUR; UFT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 0031673819     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303481     Document Type: Article

References (35)

1. Foster JH, Berman MM. Resection of metastatic tumors. Solid liver tumours. Major Problems in Clinical Surgery. Philadelphia: WB Saunders, 1977;209-35.
2. Hughes KS, Simon R, Songhorabodi S. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278-84.
3. Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978;135:389-94.
4. Fortner JG, Silva JS, Golbey RB, Cox EB, MacLean BJ. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann Surg 1984;199: 306-16.
5. Fujii S, Kitano S, Ukenaka K, Shirasaka T. Effect of co-administration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2 tetrahydrofuyl)-5-fluorouracil and level of 5-fluorouracil in rodens. Gann 1979;70:209-14.
6. Harada M, Nishitani H, Koga K, Miura I, Umeno Y. Metabolism of tegafur in rat liver observed by in vivo 19F magnetic resonance spectroscopy and chromatography. Jpn J Cancer Res 1992;83: 387-91.
7. Tolamide H, Akiyoshi H, Minato Y, Okuda H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 1977;68:553-60.
8. Falcone A, Pfanner E, Ricci S, et al. Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. Ann Oncol 1994;5:760-2.
9. Ueno M, Ohta H, Hori M, et al. Hepatic resection for colorectal liver metastasis influence on survival of clinical factors and surgery [in Japanese]. Jpn J Coloproctology [Nihon daichokoumonbyo kaishi] 1991;44:38-45.
10. Beckurts KTE, Holscher AH, Thorban St, Bollschweiler E, Siewert JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997;84: 1081-4.
11. Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum 1988;31:1-4.
12. Sugihara K, Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 1993;80:1032-5.
13. Cady B, Stone MD, McDermott WV, et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastasis. Arch Surg 1992;127:561-9.
14. Ekberg H, Tranberg K-G, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987;11:541-7.
15. Iwatsuki S, Esquivel CO, Gordon RD, Starzl TE. Liver resection for metastatic colorectal cancer. Surgery 1986;100:804-10.
16. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery 1994;116:703-11.
17. Rosen CB, Nagorney DM, Taswell HF, Helgeson SL, Ilstrup DM, van Heerden JA, Adson MA. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992;216:493-505.
18. Chang A, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
19. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;B34:187-220.
20. Hohn DC, Stagg RJ, Friedmann MA, Hannigan JF Jr, Raynor A, Ignoffo RJ. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-54.
21. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65.
22. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J. Intra-arterial floxiuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990;125:1022-7.
23. Meta-analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
24. Kemeny N, Goldberg D, Beatty D, et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986;57:492-8.
25. Lygidakis NJ, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. Hepatogastroenterology 1995;42:155-61.
26. Okuno K, Shigeoka H, Lee YS, et al. Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepatogastroenterology 1996;43:688-91.
27. Archer SGM, Gray BN. Vascularization of small liver metastases Br J Surg 1989;76:545-8.
28. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-6.
29. Tsujitani S, Watanabe A, Kakeji Y, Maehara Y, Tomoda H, Furusawa M, Sugimachi K. Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. Eur J Surg Oncol 1991;17:526-9.
30. Davis HL. Chemotherapy of large bowel cancer. Cancer 1982;50: 2638-46.
31. Malik STA, Talbot D, Clarke PI. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990;62:1023-5.
32. Baron MG, Feliu J, Biron CG, et al. UFT modulated with leucovorin in advanced colorectal cancer: oncopaz experience. Oncology 1997;54(suppl 1):24-9.
33. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12: 2296-300.
34. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E, Ho DH. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Am Soc Clin Oncol 1996;14:474.
35. Patt YZ, McBride CM, Ames FC, et al. Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. Cancer 1987;59:867-73.